Arm Holdings plc - American Depositary Shares (ARM)
286.68
+0.00 (0.00%)
NASDAQ· Last Trade: Aug 7th, 4:12 AM EDT
Detailed Quote
Previous Close
286.68
Open
-
Bid
287.50
Ask
291.00
Day's Range
N/A - N/A
52 Week Range
100.02 - 452.70
Volume
1,498
Market Cap
-
PE Ratio (TTM)
382.24
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
6,329,530
Chart
About Arm Holdings plc - American Depositary Shares (ARM)
Arm Holdings plc is a leading technology company that specializes in semiconductor and software design, primarily focusing on microprocessor and system-on-chip (SoC) architectures. Its innovative designs are integral to a wide range of applications, from mobile devices to embedded systems and Internet of Things (IoT) products. Arm's technology enables low power consumption and efficient performance, making it a popular choice among manufacturers and developers in the electronics industry. The company collaborates closely with partners to drive the advancement of next-generation computing and connectivity solutions, playing a crucial role in shaping the future of digital devices and applications. Read More
The HEAL and RISE initiative expands into a tri-country movement supporting youth and women's mental health through expanded awareness, advocacy, and community programs across three nations, by Beyond The Call 24/7.
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Chief Executive O
Church & Dwight delivered a positive second quarter, with management highlighting broad-based organic sales growth across its divisions and strong consumer d...
Best PRP P-Shot Clinic in Dubai | Glamorous Clinic in DubaiMen’s wellness is an important part of confidence, comfort, and overall quality of life. With ad
ALPHARETTA, GA - August 05, 2026 - Complete Family Healthcare provides whiplash treatment as part of its chiropractic services for patients recovering from motor vehicle accidents and other incidents that...
The company's 2018 decision to stop reporting unit sales in 2019 means investors aren't seeing the full bullish story. Fortunately, IDC is still keeping score.
Arm Holdings (ARM) stock surged over 11% on Tuesday after analysts highlighted 100%+ year-over-year data center royalty growth and strong AI chip demand.
Modern enterprise security teams face endless streams of network alerts every day. Organizations deploy a unified security platform to consolidate critical
For years, biotech investors have often evaluated oncology companies through familiar milestones, including tumor response rates, progression-free survival, and regulatory designations. While each remains important, another endpoint has begun attracting greater attention from researchers and clinicians alike: overall survival .
Turkey drew roughly 1.5 million international health patients in 2024 and around $3 billion in related revenue, according to figures published by USHAŞ, the health ministry's international services arm. Forecasters expect the market to reach $4.6 billion in 2026 and roughly $9.5 billion by 2031, with dentistry and hair transplantation carrying most of the volume.
San Antonio, Texas - August 04, 2026 - Alamo Mobile Chiropractic provides neck pain relief in Bexar County. The practice delivers mobile chiropractic care focused on addressing cervical spine issues...
VeloRESET has published a guide to help parents better understand what happens after a little league shoulder diagnosis, including why medical clearance alone may not indicate a young pitcher is ready to return to throwing.
The consensus bottom-line forecasts most investors were comparing its results to didn't appear to factor in changes stemming from a recent spinoff, or any one-time costs related to it.
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
President and Chief Executive Officer Eran Ophir described the
Washington's drone strategy is accelerating on two fronts: pouring unprecedented capital into domestic production while aggressively targeting the supply chains...
